Medgadget - (Tuesday February 14, 2023)
Daily Reads/ Medgadget A team at Rice University has developed an automated feeding platform for mosquitoes that allows researchers to test different types of repellent and investigate mosquito-borne disease transmission. Traditionally, such mosquito research would require human volunteers or animal subjects for the mosquitos to feed on, but this is obviously inconvenient and a little distasteful. This new system dispenses with the need for human volunteers and associated laborious data collection and analysis. The technology consists of 3D printed synthetic skin with real blood that flows through small vessels. Mosquitos can feed through the skin and are kept in place in a surrounding […]…
Healthcare IT news - (Tuesday February 14, 2023)
Frequent Updates/ Healthcare IT News On February 13, the government leaders thanked the Office of the National Coordinator for Health IT and six Qualified Health Information Networks (QHIN) for working to create a nationwide interoperability network under the 21st Century Cures Act. The ‘Network of Networks’
At the U.S. Department of Health and Human services, Secretary Xavier Becerra presented certificates of recognition to the CommonWell Health Alliance, eHealth Exchange, Epic TEFCA Interoperability Services, Health Gorilla, Kno2 and KONZA for moving into the pre-production testing process of the Trusted Exchange Framework and the Common Agreement.
With the framework, ONC and the Sequoia Project, TEFCA’s recognized coordinating entity, seek to establish… |
Medgadget - (Tuesday February 14, 2023)
Daily Reads/ Medgadget Researchers at the Harvard Wyss Institute have developed an electrochemical device, called the eRapid sensor, that can assist clinicians in quickly characterizing someone’s COVID-19 infection, including identifying the infecting viral variant and the nature of someone’s immunity to the virus in terms of whether it is vaccine-mediated or natural immunity. Monitoring these characteristics could help to personalize treatment for individuals and also provide data for drug development and inform government decisions on the best way to manage COVID-19 in the community. When antibodies from a blood sample bind within the device, it precipitates a biochemical cascade that affects the electrical […]…
Medgadget - (Tuesday February 14, 2023)
Daily Reads/ Medgadget Researchers at Nagoya University in Japan have developed a nanowire assay that can be used to capture and detect specific extracellular vesicles in a urine sample that indicate the presence of a brain tumor. These extracellular vesicles are naturally excreted in the urine but techniques to capture and analyze them have been complex, requiring different pieces of equipment, until now. This all-in-one assay uses a simple well plate that has been coated with zinc oxide nanowires that extracellular vesicles are attracted to because of their surface electrical charge. Then, the researchers can detect tumor-specific extracellular vesicles in each well using […]… |
Healthcare IT news - (Tuesday February 14, 2023)
Frequent Updates/ Healthcare IT News A half-dozen organizations on Monday were approved by the Department of Health and Human Services as the inaugural batch of candidates to participate as qualified health information networks as part of ONC’s Trusted Exchange Framework and Common Agreement.During a Feb. 13 event at the U.S. Department of Health and Human Services, six healthcare organizations were approved to implement TEFCA as prospective QHINs: CommonWell Health Alliance, eHealth Exchange, Epic TEFCA Interoperability Services, Health Gorilla, Kno2, and KONZA National Network.
In a blog post, National Coordinator for Health IT Micky Tripathi recognized those organizations, “for their willingness to voluntarily step up and meet the… |
DistilINFO Hospital IT - (Tuesday February 14, 2023)
Daily Reads/ DistilINFO Hospital IT – More than 95 percent of certified health IT developers met the Cures Act Final Rule compliance deadline to provide customers with new technology, according to an ONC HealthITBuzz blog post. The Cures Act Final Rule mandated many changes to the Certification Program, including four updates set to have long-lasting interoperability impacts on patients, clinicians, and developers. ONC Certified Health IT developers must: Advance interoperability for patients and providers through the use of FHIR-based application programming interfaces (APIs);Enable patients, providers, and other stakeholders to have access to consistent data elements represented in at least version one of the United States Core…
DistilINFO Hospital IT - (Tuesday February 14, 2023)
Daily Reads/ DistilINFO Hospital IT – Meeting patient needs for mental healthcare access will require industry leaders, clinicians, and healthcare policymakers to focus on giving clinicians the tools needed to meet patients in any care setting, as well as enable more ample access to mental healthcare providers, according to a new paper from the Alliance for Patient Access (AfPA). More patients than ever are seeking mental healthcare, with AfPA citing figures that 53 million Americans now live with some kind of mental illness. Exacerbated by the COVID-19 pandemic, this prevalence of mental illness has pushed the mental health space to face unheard-of patient demand. But patients… |
AuDigitalHealth - (Tuesday February 14, 2023)
AuDigitalHealth/ Videos The Summit on Clinical Governance in Digital Health was an in-person and virtual event that took place in Sydney on 7 February 2023, and was a collaboration with the Australian Commission on Safety and…
MedCity News - (Tuesday February 14, 2023)
Frequent Updates/ MedCity News G1 Therapeutics’ approach to cancer does not kill tumors. Instead, the biotech’s drug, trilaciclib, protects bone marrow from the damaging effects of chemotherapy, reducing the duration and severity of the problems that can limit the use of this cancer treatment. Since trilaciclib’s initial approval insmall cell lung cancer, G1 has pursued more clinical trials that could support expanding the drug to other cancers. Colorectal cancer will no longer be one of them.
On Monday, G1 reported preliminary data showing that the placebo group outperformed the trilaciclib arm in helping patients live longer. G1 said it has decided to stop the colorectal cancer… |